Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery (CARLHA)

Trial Profile

Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery (CARLHA)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Mar 2019

At a glance

  • Drugs Abiraterone acetate (Primary) ; LHRH receptor agonists; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Acronyms CARLHA
  • Most Recent Events

    • 28 Mar 2019 New source identified and integrated European Clinical Trials Database
    • 07 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top